Q4 2020 Pitchbook/NVCA Venture Monitor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Download IPO Report
Donnelley Financial Solutions US IPO Report - December 2020 Edition Congratulations to the 74 December issuers and their advisors on the ~$159 Billion "2020 - an unforgettable year for IPOs! successful completion of their IPO. As I look back on all the successes we Total Raised in 2020 DFIN was proud to have serviced shared with our clients - perseverance, AbCellera Biologics, Altitude hard work, compassion, and great Acquisition, BioAtla, CBRE partnerships led us to successfully Acquisition, 17 Education & 2020 Priced (count) complete 197 IPOs during a year with Technology Group, 4D Molecular 100 so many challenges. An incredibly Therapeutics, Wish, DoorDash, active pipeline, robust valuations, Far Peak Acquisition, Golden vaccine deployment and newfound Falcon Acquisition, Gores hope brings much optimism for 2021." Holding VI, Marquee Raine CRAIG CLAY, PRESIDENT, DONNELLEY FINANCIAL SOLUTIONS 0 Acquisition, Periphas Capital JAN FEB MAR APR MAY JUNE JULY AUG SEP OCT NOV DE… Partnering, Pharming Group NV, Silverback Therapeutics, Thayer 91 League Table *Top 25 Ventures Acquisition, Upstart Issuer's Counsel Count Holdings, and the largest offering IPOs publicly filed in December Ellenoff Grossman 48 this year Airbnb! bringing total count for 2020 to 621. In Kirkland & Ellis 41 2019, there were 293 total filings and Skadden Arps 38 Latham & Watkins LLP 33 296 in 2018. 156 of 2020 filings are Cooley LLP 30 December Priced (count) pending pricing. Goodwin Procter 27 2017 (15) White & Case 23 Davis Polk 19 Sector Breakdown (non-SPACs) 2018 (17) Loeb & Loeb 16 Wilson Sonsini 16 49.8% Healthcare 2019 (13) Winston & Strawn 15 24.08% Technology Ropes & Gray 14 2020 (74) Weil Gotshal 14 11.42% Consumer 2020 Priced Simpson Thacher 11 7.35% Industrial Graubard Miller 9 Greenberg Traurig 9 7.35% Financial 50% of the priced IPOs in 2020 were Paul Weiss 7 SPACs with a total count for the year Sheppard Mullin 7 WilmerHale 7 248 with a total valuation of ~$76 Healthcare Fenwick & West 6 billion. -
Capital International Fund
Capital International Fund Audited Annual Report 2020 For the year ended 31 December 2020 Société d’Investissement à Capital Variable organised under the laws of the Grand Duchy of Luxembourg R.C.S. Luxembourg B 8833 1RVXEVFULSWLRQFDQEHDFFHSWHGRQWKHEDVLVRIWKHÀQDQFLDOUHSRUWV6XEVFULSWLRQVDUHRQO\YDOLGLIWKH\DUHPDGHRQWKHEDVLVRIWKH prospectus accompanied by the latest annual report and the latest semi-annual report, if published thereafter. Capital International Fund Audited Annual Report for the year ended 31 December 2020 Contents Report of the Board of Directors of the Company to the shareholders .............. 2 Summary information ..................................................... 4 Results (unaudited) ....................................................... 17 Historical data ........................................................... 36 Portfolio breakdown ....................................................... 52 Schedule of investments ................................................... 76 Capital Group New Perspective Fund (LUX) ............................. 76 Capital Group Global Equity Fund (LUX) ................................ 88 Capital Group World Growth and Income (LUX) .......................... 94 Capital Group World Dividend Growers (LUX) ........................... 104 Capital Group New Economy Fund (LUX) ............................... 108 Capital Group New World Fund (LUX) .................................. 115 Capital Group Emerging Markets Growth Fund (LUX) ..................... 131 Capital Group Japan Equity Fund -
Bryce Start-Up Space 2017
Start-Up Space Update on Investment in Commercial Space Ventures 2017 Formerly Tauri Group Space and Technology Contents Executive Summary . i Introduction . 1 Purpose and Background . 1 Methodology . 1 Overview of Start-Up Space Ventures. 4 Overview of Space Investors .......................6 Space Investment by the Numbers ................13 Seed Funding . 14 Venture Capital . 15 Private Equity . 17 Acquisition . 17 Public Offering . 17 Debt Financing . 18 Investment Across All Types . 18 Valuation . 19 Space Investors by the Numbers ..................20 Overall . 20 Angels . 23 Venture Capital Firms . 25 Private Equity Groups . 28 Corporations . 29 Banks and Other Financial Institutions . 31 Start-Up Space: What’s Next? . 32 Acknowledgements .............................34 3 Executive Summary he Start-Up Space series examines space investment in the 21st century and analyzes Tinvestment trends, focusing on investors in new companies that have acquired private financing. Space is continuing to attract increased attention in Silicon Valley and in investment communities world-wide . Space ventures now appeal to investors because new, lower-cost systems are envisioned to follow the path terrestrial tech has profitably traveled: dropping system costs and massively increasing user bases for new products, especially new data products . Large valuations and exits are demonstrating the potential for high returns . Start-Up Space reports on investment in start-up space ventures, defined as space companies that began as angel- and venture capital-backed start-ups . The report tracks seed, venture, and private equity investment in start-up space ventures as they grow and mature, over the period 2000 through 2016. The report includes debt financing for these companies where applicable to provide a complete picture of the capital available to them and also highlights start-up space venture merger and acquisition (M&A) activity . -
Citigroup Jefferies SVB Leerink
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232543 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED SEPTEMBER 17, 2019 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 19, 2019) $90,000,000 Common Stock We are offering $90,000,000 of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol “TBIO”. The last reported sale price of our common stock on the Nasdaq Global Select Market on September 16, 2019 was $10.58 per share. Investing in our common stock involves risks. See “Risk Factors” beginning on page S-11 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. Per Share Total Public Offering Price $ $ Underwriting Discounts and Commissions(1) $ $ Proceeds to Translate Bio, Inc. (before expenses) $ $ (1) We refer you to “Underwriting” beginning on page S-23 of this prospectus supplement for additional information regarding underwriter compensation. -
Back Bay Life Science Advisors Investment Banking Title of Newsletter
BACK BAY LIFE SCIENCE ADVISORS INVESTMENT BANKING TITLE OF NEWSLETTER RECENT BIOPHARMA – MEDTECH DEAL HIGHLIGHTS This month we say goodbye to winter and welcome springtime with meals that reflect the transition between seasons. Take a look and find something new to add to your own favorites. OF NOTE FROM THE MARKET - The market was relatively steady last week, with a positive end to the week, which ended a 3 week losing streak: S&P 500 +2.6%; Nasdaq 3.1% (S&) 500 finished at a 52 week high o Market performance shows that the economy is heating up as unemployment decreases, the promise of the discal stimulus bill starts to take effect and growth seen across the market, even in value stocks - Strength in market also seen from IPOs with already 302 IPOS in the year that have raised $102B, an increased of 763% from 2020 o 80% of these offerings are SPACs- for all of 2020 there were 457 IPOS and prior to that the record was 547 o Approximately 60% of SPACs that have acquired businesses between 2016-2020 have lagged the S&P 500 DEAL, FINANCING, AND CLINICAL SNAPSHOT Indices % Change in Performance (1 Year) 130.0% NASDAQ NBI % Change 110.0% NASDAQ Composite % Change 90.0% DJSMDQ Composite % Change 70.0% 50.0% 30.0% 10.0% (10.0%) (30.0%) 3/16/2020 4/16/2020 5/16/2020 6/16/2020 7/16/2020 8/16/2020 9/16/2020 1/16/2021 2/16/2021 10/16/2020 11/16/2020 12/16/2020 As Indices % Change in Performance (1 Month) 120.0% 100.0% 80.0% 60.0% 40.0% NASDAQ NBI % Change 20.0% NASDAQ Composite % Change 0.0% DJSMDQ Composite % Change 3/2/2021 3/5/2021 3/8/2021 2/12/2021 2/15/2021 2/18/2021 2/21/2021 2/24/2021 2/27/2021 3/11/2021 BIOPHARMA-MEDTECH FINANCINGS OF NOTE RECENT BIOPHARMA FINANCINGS Bookrunners / Lead + New Amount Company Description Deal Type Investors Raised ($M) Proceeds will be used to effect a business Frontier combination with one or more businesses in the SPAC Credit Suisse, Berenberg $200 Acquisition biotech space. -
Building for the Future
FEBRUARY 2019 CONSTRUCTION & TECHNOLOGY: BUILDING FOR THE FUTURE CONSTRUCTION & TECHNOLOGY: BUILDING FOR THE FUTURE ABOUT THE AUTHOR Navitas Capital is a venture capital firm focused on early-stage technology investments for the real estate and construction industries. Current and past portfolio companies include Katerra, PlanGrid (Autodesk), Matterport, Truss, HqO, Bowery, Aquicore, Livly, Gridium, View, Honest Buildings, Harbor, PeerStreet, Sweeten, Comfy (Siemens) and Can2Go (Schneider Electric). Navitas offers a unique perspective on the built world spanning multiple venture capital funds since 2011, as well as the partners’ own experience owning, managing, and developing over $1B in real estate assets. Navitas’ combination of venture capital & real estate experience, along with the ability to test and deploy cutting-edge technology across its own portfolio, creates a unique investment platform for its portfolio companies and limited partners. Beyond its own capital and real estate, Navitas helps startups scale rapidly by facilitating access to Navitas' network of industry leading LPs with global scale. Navitas’ investment strategy is to provide a combination of growth capital, industry expertise, and market access to high growth technology companies. Navitas is currently investing out of its second VC fund that includes anchor strategic commitments from a number of industry leading LPs. Please visit our website for more information. NORTHERN CALIFORNIA 1111 Broadway Ave. Oakland, CA 94608 SOUTHERN CALIFORNIA 9460 Wilshire Blvd. Suite -
1Life Healthcare, Inc. (Q1 2021 Earnings)
1Life Healthcare, Inc. (Q1 2021 Earnings) May 12, 2021 Corporate Speakers: Rose Salzwedel; 1Life Healthcare, Inc.; Director of IR Amir Rubin; 1Life Healthcare, Inc.; Chair, CEO & President Bjorn Thaler; 1Life Healthcare, Inc.; CFO Participants: Ryan Daniels; William Blair & Company L.L.C.; Partner & Co-Group Head of Healthcare Technology and Services Lisa Gill; JPMorgan Chase & Co; MD, Head of U.S. Healthcare Technology & Distribution Equity Research and Senior Research Analyst Elizabeth Anderson; Evercore ISI Institutional Equities; Associate George Hill; Deutsche Bank AG; MD & Equity Research Analyst Stephanie Wissink; Jefferies LLC; Equity Analyst and MD Alexander Draper; Truist Securities, Inc.; MD of Equity Research Connor Oleferchik; Morgan Stanley; Research Associate Richard Close; Canaccord Genuity Corp.; MD & Senior Analyst Daniel Grosslight; Citigroup Inc.; Research Analyst Stephanie Davis; SVB Leerink LLC; MD of Healthcare Technology and Distribution Jessica Tassan; Piper Sandler & Co.; Research Analyst Carlos Consuegra; Credit Suisse AG; Research Analyst PRESENTATION Operator: Ladies and gentlemen, thank you for standing by, and welcome to the One Medical First Quarter 2021 Earnings Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker for today, Rose Salzwedel, Head of Investor Relations. You may begin. Rose Salzwedel: Thank you, operator. Hello, everyone, and welcome to One Medical Fiscal 2021 First Quarter Earnings Call. I am joined today by Amir Dan Rubin, Chair and CEO of One Medical; and Bjorn Thaler, Chief Financial Officer of One Medical. A complete disclosure of our results can be found in our press release issued earlier today as well as in our related Form 8-K, all of which are available on our website at investor.onemedical.com. -
$150000000 Bofa Securities Jefferies SVB Leerink
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-227182 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED FEBRUARY 10, 2021 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated September 4, 2018) $150,000,000 Common Stock We are offering $150,000,000 of shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “TVTX.” On February 9, 2021, the last reported sale price of our common stock on The Nasdaq Global Market was $30.05 per share. Based on an assumed public offering price of $30.05 per share, the last reported sale price of our common stock on The Nasdaq Global Market on February 9, 2021, we would expect to offer approximately 4,991,680 shares hereby. Investing in our common stock involves risks. See “Risk Factors” on page S-7 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement. PER SHARE TOTAL Public offering price $ $ Underwriting discounts and commissions (1) $ $ Proceeds to Travere (before expenses) $ $ (1) See “Underwriting” for additional disclosure regarding underwriting compensation. We have granted the underwriters an option for a period of 30 days to purchase up to an additional $22,500,000 of common stock on the same terms set forth above. -
Start-Up Space Report 2020
Start-Up Space Update on Investment in Commercial Space Ventures 2020 i Bryce Space and Technology brycetech.com CONTENTS EXECUTIVE SUMMARY ........................................... III INTRODUCTION. 1 Purpose and Background . 1 Methodology ...................................................1 OVERVIEW OF START-UP SPACE VENTURES. 3 TYPES OF SPACE INVESTOR ......................................4 SPACE INVESTMENT BY THE NUMBERS ...........................11 Seed Funding . 15 Venture Capital . 16 Private Equity . 17 Acquisition ...................................................18 Public Offering ................................................19 Debt Financing . 19 Investment Across All Types .....................................19 Valuation ....................................................21 Casualties ...................................................22 SPACE INVESTORS BY THE NUMBERS ............................23 Overall ......................................................23 Angels ......................................................27 Venture Capital Firms . 28 Private Equity Groups ..........................................31 Corporations . 32 Banks and Other Financial Institutions .............................33 SPECIAL TOPIC: CHINESE ACTIVITY IN START-UP SPACE VENTURES. 35 START-UP SPACE: WHAT’S NEXT?. 38 ACKNOWLEDGEMENTS. 41 ii brycetech.com Bryce Space and Technology EXECUTIVE SUMMARY Three significant trends are shaping the start-up space environment as we enter the 2020s. First, investors continue to pour large amounts -
The-Business-Of-Venture-Capital-1
The Business of Venture Capital By Jeff Weinstein November 5th, 2020 What is Venture Capital? • A subset of private equity (investing in private companies for a piece of ownership) financing. • Typically (but not exclusively) focused on early-stage high risk, young technology companies since those companies often have the highest growth potential. • Unlike PE, typically take minority stakes in companies and do not exert control. • Many of the most important companies in the U.S. (and virtually all its important tech companies) were venture-funded. History of Venture Capital • Business model began with whaling in the mid 1800s. • Unpredictable, high-risk, high-reward venture. • Returns follow a power-law distribution. Most ships would lose money, but a few were VERY profitable, making it a profitable endeavor on the whole. • Investors would collect large pots of money and diversify across multiple whaling ships to generate massive returns. • Average whaling vessel spent 3 years at sea! • Captains would be compensated by keeping a percentage of the profits. Origin of carried interest! Modern VC Structure • VCs are managed by General Partners “GPs”. • GPs typically put in 2% of the total fund as GP commit. • Typical VC fund charges “2 and 20” : 2% per year Management Fee, 20% Carried Interest • 10 year lockup + options for two 1 year extensions • 3-5 year investment period (sometimes higher fees up front that lower during “harvest period” • Capital is committed in entirety but only “called” in small tranches over first 3-5 years • Both carried interest and partnership gains are taxed as long-term capital gains (lower than ordinary incomes) History of Venture Capital • First VC “fund” in 1946 with ARD (American Research and Development) Corporation and J.H. -
Responsible Investing in Tech and Venture Capital [PDF]
TECHNOLOGY AND PUBLIC PURPOSE PROJECT Responsible Investing in Tech and Venture Capital Advancing Public Purpose in Frontier Technology Companies Susan Winterberg FACULTY DIRECTOR Laura Manley Ash Carter Karen Ejiofor Amritha Jayanti Joseph Fridman Sam Lambert Marta Zwierz PAPER AUGUST 2020 Technology and Public Purpose Project Belfer Center for Science and International Affairs Harvard Kennedy School 79 JFK Street Cambridge, MA 02138 www.belfercenter.org/TAPP Statements and views expressed in this report are solely those of the author and do not imply endorsement by Harvard University, Harvard Kennedy School, or the Belfer Center for Science and International Affairs. Design and layout by Andrew Facini Copyright 2020, President and Fellows of Harvard College Printed in the United States of America TECHNOLOGY AND PUBLIC PURPOSE PROJECT Responsible Investing in Tech and Venture Capital Advancing Public Purpose in Frontier Technology Companies Susan Winterberg FACULTY DIRECTOR Laura Manley Ash Carter Karen Ejiofor Amritha Jayanti Joseph Fridman Sam Lambert Marta Zwierz PAPER AUGUST 2020 About the Project The arc of innovative progress has reached an inflection point. Technological change has brought immeasurable benefits to billions through improved health, productivity, and convenience. Yet as recent events have shown, unless we actively manage their risks to society, new technologies may also bring unforeseen destructive consequences. Making technological change positive for all is the critical challenge of our time. We ourselves - not only the logic of discovery and market forces - must manage it. To create a future where technology serves humanity as a whole, we need a new approach. To this end, Harvard Kennedy School’s Belfer Center for Science and International Affairs has launched a new endeavor, the Technology and Public Purpose (TAPP) Project. -
Topics in Entrepreneurial Finance FINC-UB61 | Spring 2016 | Tuesday-Thursday | Section 1: 9:30-10:45 | Section 2: 11-12:15
Topics in Entrepreneurial Finance FINC-UB61 | Spring 2016 | Tuesday-Thursday | Section 1: 9:30-10:45 | Section 2: 11-12:15 Assistant ProFessor Sabrina T. Howell TAs: TBD Draft Syllabus (11/3/2015) CLASS OVERVIEW This course will explore how high-growth new ventures (i.e. startups) are founded and funded. We will initially focus on the entrepreneur’s perspective, and then shiFt to the financier’s perspective as we study the venture capital industry. Entrepreneurial finance is characterized by large amounts oF uncertainty, and one aim oF the course is to learn how to balance good qualitative judgment with quantitative valuation. Due to the inherently ambiguous nature oF many decisions that early stage investors and entrepreneurs face, this course will be less quantitative/mathematical than most Finance courses. IF you are uncomfortable with more qualitative/non-Formulaic approaches to problems, then this course is not For you. We will Follow a successFul startup’s path From opportunity recognition and company founding through the stages of new venture finance. Part I of the course takes the entrepreneur’s perspective. You will learn how to develop a business plan for a new idea and pitch it to investors. We will also develop the core skills oF valuation. Then we will study the venture capital industry and learn how VCs make deals with startups (Part II). The third part oF the course will examine experimentation in entrepreneurial Finance. In the final part oF the course, we will examine how entrepreneurs and investors realize returns, and discuss the IPO process (Part III). This course will use a mixture oF cases, lectures, and outside speakers.